DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway

被引:0
作者
S Ocak
H Yamashita
A R Udyavar
A N Miller
A L Gonzalez
Y Zou
A Jiang
Y Yi
Y Shyr
L Estrada
V Quaranta
P P Massion
机构
[1] Pulmonary and Critical Care Medicine,Division of Allergy
[2] Vanderbilt University,Department of Cancer Biology
[3] Vanderbilt University,Department of Pathology
[4] Vanderbilt University,Division of Genetic Medicine
[5] Cancer Biostatistics Center,undefined
[6] Vanderbilt University,undefined
[7] Vanderbilt University,undefined
[8] Vanderbilt-Ingram Comprehensive Cancer Center,undefined
[9] Veterans Affairs Medical Center,undefined
来源
Oncogene | 2010年 / 29卷
关键词
array CGH; copy number alterations; pathway analysis; FAK; adhesion; spreading;
D O I
暂无
中图分类号
学科分类号
摘要
Small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer in its clinical behavior, with a 5-year overall survival as low as 5%. Despite years of research in the field, molecular determinants of SCLC behavior are still poorly understood, and this deficiency has translated into an absence of specific diagnostics and targeted therapeutics. We hypothesized that tumor DNA copy number alterations would allow the identification of molecular pathways involved in SCLC progression. Array comparative genomic hybridization was performed on DNA extracted from 46 formalin-fixed paraffin-embedded SCLC tissue specimens. Genomic profiling of tumor and sex-matched control DNA allowed the identification of 70 regions of copy number gain and 55 regions of copy number loss. Using molecular pathway analysis, we found a strong enrichment in these regions of copy number alterations for 11 genes associated with the focal adhesion pathway. We verified these findings at the genomic, gene expression and protein level. Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines. Those were poorly adherent to most substrates but not to laminin-322. Inhibition of FAK phosphorylation at Tyr397 by a small-molecule inhibitor, PF-573,228, induced a dose-dependent decrease of adhesion and an increase of spreading in SCLC cell lines on laminin-322. Cells that tended to spread also showed a decrease in focal adhesions, as demonstrated by a decreased vinculin expression. These results support the concept that pathway analysis of genes in regions of copy number alterations may uncover molecular mechanisms of disease progression and demonstrate a new role of FAK and associated adhesion pathways in SCLC. Further investigations of FAK at the functional level may lead to a better understanding of SCLC progression and may have therapeutic implications.
引用
收藏
页码:6331 / 6342
页数:11
相关论文
共 50 条
  • [21] Genomic Copy Number Signatures Uncovered a Genetically Distinct Group from Adenocarcinoma and Squamous Cell Carcinoma in Non-Small Cell Lung Cancer
    Lee, Eunjung
    Moon, Ji Wook
    Wang, Xianfu
    Kim, Chungyeul
    Li, Shibo
    Shin, Bong Kyung
    Jung, Wonkyung
    Kim, Hyun Koo
    Kim, Han Kyeom
    Lee, Ji-Yun
    HUMAN PATHOLOGY, 2015, 46 (08) : 1111 - 1120
  • [22] Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer
    Ji, Hong-Fei
    Pang, Da
    Fu, Song-Bin
    Jin, Yan
    Yao, Lei
    Qi, Ji-Ping
    Bai, Jing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (03) : 429 - 435
  • [23] DNA Copy Number Aberrations and Disruption of the p16Ink4a/Rb Pathway in Radiation-Induced and Spontaneous Rat Mammary Carcinomas
    Iizuka, Daisuke
    Imaoka, Tatsuhiko
    Takabatake, Takashi
    Nishimura, Mayumi
    Kakinuma, Shizuko
    Nishimura, Yukiko
    Shimada, Yoshiya
    RADIATION RESEARCH, 2010, 174 (02) : 206 - 215
  • [24] Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
    Howe, Grant A.
    Xiao, Bin
    Zhao, Huijun
    Al-Zahrani, Khalid N.
    Hasim, Mohamed S.
    Villeneuve, James
    Sekhon, Harmanjatinder S.
    Goss, Glenwood D.
    Sabourin, Luc A.
    Dimitroulakos, Jim
    Addison, Christina L.
    PLOS ONE, 2016, 11 (03):
  • [25] YAP silencing by RB1 mutation is essential for small-cell lung cancer metastasis
    Wu, Zhengming
    Su, Junhui
    Li, Fu-long
    Chen, Tao
    Mayner, Jaimie
    Engler, Adam
    Ma, Shenghong
    Li, Qingquan
    Guan, Kun-Liang
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [26] Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
    Tang, Ke-Jing
    Constanzo, Jerfiz D.
    Venkateswaran, Niranjan
    Melegari, Margherita
    Ilcheva, Mariya
    Morales, Julio C.
    Skoulidis, Ferdinandos
    Heymach, John V.
    Boothman, David A.
    Scaglioni, Pier Paolo
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5851 - 5863
  • [27] Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis
    Lo, Ken C.
    Stein, Leighton C.
    Panzarella, Jenniffer A.
    Cowell, John K.
    Hawthorn, Lesleyann
    LUNG CANCER, 2008, 59 (03) : 315 - 331
  • [28] Pathway Targets to Explore in the Treatment of Non-small Cell Lung Cancer
    Weiss, Glen J.
    Kingsley, Chris
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (11) : 1342 - 1352
  • [29] In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways
    Kraus, AC
    Ferber, I
    Bachmann, SO
    Specht, H
    Wimmel, A
    Gross, MW
    Schlegel, J
    Suske, G
    Schuermann, M
    ONCOGENE, 2002, 21 (57) : 8683 - 8695
  • [30] In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways
    Alison C Kraus
    Ines Ferber
    Sven-Oliver Bachmann
    Hannah Specht
    Anja Wimmel
    Markus W Gross
    Juergen Schlegel
    Guntram Suske
    Marcus Schuermann
    Oncogene, 2002, 21 : 8683 - 8695